M Boegemann1, A J Schrader2, K Rahbar3. 1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland. martin.boegemann@ukmuenster.de. 2. Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland. 3. Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland.
Abstract
BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and 223Ra), most of these patients still succumb to prostate cancer. Recently, 177lutetium prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy. OBJECTIVES: Establishment of the current position of 177Lu-PSMA-RLT in mCRPC in 2017. MATERIALS AND METHODS: Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on 177Lu-PSMA-RLT after PubMed-based research. RESULTS: In several larger retrospective studies, 177Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile. CONCLUSIONS: Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with 177Lu-PSMA-RLT in the treatment of mCRPC.
BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and 223Ra), most of these patients still succumb to prostate cancer. Recently, 177lutetium prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy. OBJECTIVES: Establishment of the current position of 177Lu-PSMA-RLT in mCRPC in 2017. MATERIALS AND METHODS: Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on 177Lu-PSMA-RLT after PubMed-based research. RESULTS: In several larger retrospective studies, 177Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile. CONCLUSIONS: Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with 177Lu-PSMA-RLT in the treatment of mCRPC.
Authors: Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes Journal: Pathol Oncol Res Date: 2008-09-18 Impact factor: 3.201
Authors: Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar Journal: J Nucl Med Date: 2016-04-07 Impact factor: 10.057
Authors: Kambiz Rahbar; Axel Bode; Matthias Weckesser; Nemanja Avramovic; Michael Claesener; Lars Stegger; Martin Bögemann Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: J Clin Oncol Date: 2017-04-06 Impact factor: 44.544
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Sigrid A Rajasekaran; Gopalakrishnapillai Anilkumar; Eri Oshima; James U Bowie; He Liu; Warren Heston; Neil H Bander; Ayyappan K Rajasekaran Journal: Mol Biol Cell Date: 2003-10-03 Impact factor: 4.138
Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler Journal: EJNMMI Res Date: 2015-06-20 Impact factor: 3.138
Authors: Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-12 Impact factor: 9.236
Authors: H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler Journal: Urologe A Date: 2018-06 Impact factor: 0.639